Pooled Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Global Market Report 2026

The pooled clustered regularly interspaced short palindromic repeats (crispr) screening market size has grown rapidly in recent years. It will grow from $1.3 billion in 2025 to $1.51 billion in 2026 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to rising demand for functional genomics, increasing adoption of crispr-cas9 technology, growth of pharmaceutical r&d, advancements in gene editing tools, expansion of academic research programs.

The pooled clustered regularly interspaced short palindromic repeats (crispr) screening market size is expected to see rapid growth in the next few years. It will grow to $2.74 billion in 2030 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to ai-enabled gene screening, integration with cloud-based genomics platforms, demand for personalized medicine applications, expansion of biotech infrastructure, automation in high-throughput screening. Major trends in the forecast period include high-throughput screening techniques, integration with multi-omics data, automated crispr workflows, ai-driven gene target identification, real-time functional genomics analysis.

The rising prevalence of genetic disorders is anticipated to drive the expansion of the pooled clustered regularly interspaced short palindromic repeats (CRISPR) screening market. Genetic disorders are conditions arising from inherited or acquired anomalies in an individual’s DNA that impact normal development, metabolism, or physiological function. The growing prevalence of these disorders is partly due to factors such as advanced parental age, enhanced diagnostic capabilities, and broader genetic screening, all contributing to increased detection and reporting rates. Pooled CRISPR screening is essential in genetic disorder research, as it enables high-throughput, genome-wide identification of disease-associated genes and regulatory pathways. For example, in October 2024, the Cystic Fibrosis Trust, a UK-based charity supporting individuals with cystic fibrosis, reported that approximately 11,148 cystic fibrosis patients were registered in 2022, rising to 11,318 in 2023, representing a year-over-year growth of around 1.5%. Consequently, the increasing prevalence of genetic disorders is fueling the growth of the pooled clustered regularly interspaced short palindromic repeats (CRISPR) screening market.

Key companies operating in the pooled clustered regularly interspaced short palindromic repeats (CRISPR) screening market are focusing on developing innovative solutions such as transcriptome-wide profiling to enable high-throughput functional genomics and precise identification of gene targets for therapeutic and research applications. Transcriptome-wide profiling refers to the comprehensive analysis of all RNA transcripts expressed in a cell or tissue at a given time, providing insights into gene activity, regulation, and cellular functions. For example, in June 2023, Parse Biosciences Inc., a US-based biotechnology company, launched CRISPR Detect, a technology enabling high-scale single-cell pooled CRISPR screens. This innovation integrates with the company's Evercode Whole Transcriptome platform to pair individual gene perturbations, via Cas12-based single guide ribonucleic acid (RNA) (sgRNAs), with whole-transcriptome expression profiles across up to one million cells per experiment, overcoming prior throughput and cost barriers in droplet-based single-cell RNA-seq. It expands applications in genome-scale gene function analysis, regulatory networks, signaling pathways, and drug discovery beyond targeted validation.

The rising research and development investments are expected to further propel the growth of the pooled clustered regularly interspaced short palindromic repeats (CRISPR) screening market. Research and development (R&D) investments involve allocating resources to create new products, enhance existing offerings, and advance technologies to foster innovation and long-term business growth. Technological advancements are encouraging higher research and development investments, as companies continuously innovate and refine products and processes to keep pace with rapid digital transformation and evolving industry standards. R&D investments support CRISPR screening by enabling the creation of advanced gene-editing tools, optimizing protocols, and improving accuracy and efficiency for faster gene function discovery. For instance, in 2023, according to the Office for National Statistics, a UK-based government agency, the UK government’s net spending on research and development (R&D) rose to £17.4 billion ($22.1 billion) in 2023, up from £16.1 billion ($20.45 billion) in 2022, marking an 8.2% increase. Therefore, the rising research and development investments are driving the growth of the pooled clustered regularly interspaced short palindromic repeats (CRISPR) screening market.

Major companies operating in the pooled clustered regularly interspaced short palindromic repeats (crispr) screening market are Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Applied Biological Materials Inc., Agilent Technologies Inc., Charles River Laboratories International Inc., QIAGEN N.V., GenScript Biotech Corporation, Twist Bioscience Corporation, Ginkgo Bioworks Inc., Element Biosciences Inc., Synthego Corporation, Bit.bio Limited, Bioneer Corporation, VectorBuilder Inc., Admera Health LLC, Addgene Inc., Creative Biogene Inc., Cellecta Inc., Vivlion Inc., GeneCopoeia Inc.

North America was the largest region in the pooled clustered regularly interspaced short palindromic repeats (CRISPR) screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pooled clustered regularly interspaced short palindromic repeats (crispr) screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pooled clustered regularly interspaced short palindromic repeats (crispr) screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pooled clustered regularly interspaced short palindromic repeats (CRISPR) screening market consists of revenues earned by entities by providing services such as CRISPR screening services, custom library design, assay development services, data analysis services, bioinformatics solutions, cell line engineering services, and validation studies. The market value includes the value of related goods sold by the service provider or included within the service offering. The pooled clustered regularly interspaced short palindromic repeats (CRISPR) screening market also includes sales of CO₂ incubators, refrigerators and freezers, and automated liquid handling robots. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream research organizations, biotechnology firms, pharmaceutical companies, and academic institutions) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pooled clustered regularly interspaced short palindromic repeats (CRISPR) screening is a high-throughput genetic method that applies CRISPR-Cas systems to simultaneously modify or knock out multiple genes in a cell population. It allows researchers to pinpoint genes involved in specific cellular functions, disease mechanisms, or drug responses by observing the effects of these targeted changes across the pooled cells.

The primary screening types of pooled clustered regularly interspaced short palindromic repeats (CRISPR) screening include genome-wide screening and targeted screening. Genome-wide screening analyzes the entire genome to identify genes, variants, or mutations associated with specific traits, diseases, or biological functions. Product types include libraries, reagents and kits, instruments, software, and services, using technologies such as CRISPR-Cas9 screening, CRISPR interference screening, and CRISPR activation screening. Applications cover functional genomics, drug discovery, cancer research, gene regulation, and other fields, serving pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and other end users.

Tariffs have influenced the pooled CRISPR screening market by increasing import costs for specialized instruments, reagents, and libraries. This impact is most significant for segments like instruments and reagents in regions such as North America and Europe that rely heavily on imports. While tariffs have temporarily slowed adoption, they are encouraging local manufacturing, investment in domestic production capabilities, and innovation in cost-effective solutions, ultimately supporting market resilience and diversification.

The pooled clustered regularly interspaced short palindromic repeats (crispr) screening market research report is one of a series of new reports that provides pooled clustered regularly interspaced short palindromic repeats (crispr) screening market statistics, including pooled clustered regularly interspaced short palindromic repeats (crispr) screening industry global market size, regional shares, competitors with a pooled clustered regularly interspaced short palindromic repeats (crispr) screening market share, detailed pooled clustered regularly interspaced short palindromic repeats (crispr) screening market segments, market trends and opportunities, and any further data you may need to thrive in the pooled clustered regularly interspaced short palindromic repeats (crispr) screening industry. This pooled clustered regularly interspaced short palindromic repeats (crispr) screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.